Evotec secures Gates grant for Covid-19 monoclonal antibody research

Via its U.S. subsidiary Just, the company has secured a grant to develop a monoclonal antibodies for low-income countries.

German biotech-CRO hybrid received an undisclosed grant amount to help develop the next generation of antibodies to combat severe forms of COVID-19 from the Bill & Melinda Gates Foundation. Channelled via Evotec’s U.S. subsidiary Just, also called Evotec Biologics, the grant is intended to support work on new monoclonal antibody (mAb) drugs as the race for a vaccine intensifies.

With several antibody candidates already in late-stage testing and with some early data showing glimpses of promise, the grant is expected to be used to research an antibody candidate to help save lives of vulnerable populations in low and middle income countries, which are likely to be left behind as the developed countries lock-in supply agreements with pharmaceutical companies as more encouraging data is reported.